Executive record

Yekaterina (Katie) Chudnovsky

Director at Elicio Therapeutics, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:yekaterina-katie-chudnovskyVersion: public-0As of: 2026-09-28

Not yet claimed7 published Claims3 sources
  • Director

Key Claims

Biography

Yekaterina Chudnovsky is an attorney, venture investor, and dedicated patient advocate with particular interest in cancer research and personalized cancer vaccines. She serves as Chairperson of the GI Research Foundation and is an active board member of xCures, a technology company with an AI-based precision oncology platform. She holds a J.D. from DePaul University and B.A. from Northwestern University.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. ELTX DEF 14A director slate

    sec filing · Source published: Apr 9, 2025 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and machine learning experience reported in filings · Claim reviewed: May 15, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  2. Open source

    sec proxy · Source published: Apr 9, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Elicio Therapeutics, Inc. · Claim reviewed: May 15, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Elicio Therapeutics, Inc. · Claim reviewed: May 15, 2026